Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Endometrial Neoplasms 1Anus Neoplasms 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4sargramostim 3pembrolizumab 3Trastuzumab 3Methods 3palbociclib 2cediranib 2Standard of Care 2Specimen Handling 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-12 Subunit p35 2Interferon-alpha 2Fluorouracil 2Fluorodeoxyglucose F18 2Erlotinib Hydrochloride 2Docetaxel 2Counseling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sapanisertib 1relatlimab 1pertuzumab 1osimertinib 1orantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × alovudine × Genitourinary × Clear all
NCT01717391 2019-03-26

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

University of Iowa

Phase 2 Completed
36 enrolled 5 charts
GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡